ATM-3507 is a potent tropomyosin inhibitor with IC 50 s from 3.83-6.84 μM in human melanoma cell lines. In Vitro The cell lines differ in their relative expression of Tpm3.1 as well as in the expression of other isoforms. After determing the IC 50 concentrations for TR100 and ATM-3507 (CHLA-20: 4.99±0.45 μM, CHP-134: 3.83±0.67 μM, CHLA-90: 6.84±2.37 μM, SK-N-BE(2): 5.00±0.42 μM) in each of the neuroblastoma cell lines, combinations of tropomyosin inhibitors plus Vincristine are tested at levels of each drug alone that kill less than 50% of the neuroblastoma cells. The combinations of both tropomyosin inhibitors plus Vincristine are completely cytotoxic in CHLA-20 cells. All 4 cell lines show some degree of synergy as determined by the Chou–Talalay method. The effect is not limited to the vinca alkaloids as a similar combination efficacy using paclitaxel plus TR100 or ATM-3507. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The maximal tolerance dose (MTD) for TR100 and ATM-3507 is 60 and 150 mg/kg, respectively. It is found that a significant inhibition of tumor growth and prolongation of animal survival using either combination compared with each monotherapy. The median survival of mice increased from 18 days for mice treated with ATM-3507 to more than 49 days for mice treated with the combination. It is also found that twice weekly intravenous administration of ATM-3507 also show combination efficacy. The impact of each treatment or the combination on body weight is minimal. Drug levels are measured following the intravenous administration of ATM-3507 at 30 mg/kg in Balb/c mice (n=3 per time point). The mean half-life of ATM-3507 is 5.01 hrs for the terminal elimination phase. The mean AUC 0-t in the plasma is 14,548 ng/h/mL. The C max of ATM-3507 is 5,758 ng/mL and the the t 1/2 is 5.01 h. The observed plasma clearance and volume of distribution at steady state of ATM-3507 is 33.8 mL/min/kg and 7.23 L/kg, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 3.83-6.84 μM (tropomyosin, in human melanoma celllines)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
ATM-3507
CAS number：1861449-70-8 molecular formula：C37H46FN5O2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | MC4FSR36T2 | NSC824722 | NSC-824722 | AKOS032960473 | ATM-3507 | Methanone, (3-((2,3-dimethyl-1-(3-(4-methyl-1-piperazinyl)propyl)-1H-indol-5-yl)oxy)phenyl)(4-(2-(4-fluorophenyl)ethyl)-1-piperazinyl)- | (3-((2,3-Dimethyl-1-(3-(4-methylpiperazin-1-yl)propy | ||
| CAS number | 1861449-70-8 | molecular formula | C37H46FN5O2 |
| molecular weight | 611.79 g/mol | Exact mass | ≥98% |
| PSA | 44.200 Ų | logp | 5.8 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
